| Drug General Information |
| Drug ID |
D0LH4L
|
| Former ID |
DNC007398
|
| Drug Name |
BOLDINE
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C19H21NO4
|
| Canonical SMILES |
CN1CCC2=CC(=C(C3=C2C1CC4=CC(=C(C=C43)OC)O)OC)O
|
| InChI |
1S/C19H21NO4/c1-20-5-4-10-7-15(22)19(24-3)18-12-9-16(23-2)14(21)8-11(12)6-13(20)17(10)18/h7-9,13,21-22H,4-6H2,1-3H3
|
| InChIKey |
LZJRNLRASBVRRX-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Neuronal acetylcholine receptor protein, beta-2 chain |
Target Info |
Inhibitor |
[1]
|
|---|
| D(2) dopamine receptor |
Target Info |
Inhibitor |
[2]
|
| Dopamine D1 receptor |
Target Info |
Inhibitor |
[2]
|
| Neuronal acetylcholine receptor protein, alpha-4 chain |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
|
Cholinergic synapse
|
|
Nicotine addictionhsa04015:Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholismhsa04020:Calcium signaling pathway
|
|
Amphetamine addiction
|
|
Morphine addiction
|
|
Alcoholismhsa04080:Neuroactive ligand-receptor interaction
|
|
Nicotine addiction
|
|
PANTHER Pathway
|
Nicotinic acetylcholine receptor signaling pathway
|
|
Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathwayP05912:Dopamine receptor mediated signaling pathwayP00044:Nicotinic acetylcholine receptor signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
PathWhiz Pathway
|
Dopamine Activation of Neurological Reward System
|
|
Reactome
|
Highly sodium permeable acetylcholine nicotinic receptors
|
|
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors
|
|
Highly calcium permeable nicotinic acetylcholine receptorsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (s) signalling eventsR-HSA-629587:Highly sodium permeable acetylcholine nicotinic receptors
|
|
Highly calcium permeable nicotinic acetylcholine receptors
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
|
Nicotine Activity on Dopaminergic NeuronsWP666:Hypothetical Network for Drug Addiction
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
GPCR downstream signalingWP706:SIDS Susceptibility Pathways
|
|
Nicotine Activity on Dopaminergic Neurons
|
| References |
| REF 1 | Bioorg Med Chem. 2007 May 15;15(10):3368-72. Epub 2007 Mar 13.Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers. |
|---|
| REF 2 | J Nat Prod. 2000 Apr;63(4):480-4.Halogenated boldine derivatives with enhanced monoamine receptor selectivity. |
|---|
